On this page
For decades, ADHD was considered primarily a childhood condition affecting boys — hyperactive, impulsive, unable to sit still in class. But a growing body of research is telling a far more complex story, one that centres on a powerful, often-overlooked player in ADHD symptomatology: hormones. From the menstrual cycle to menopause, from estrogen to cortisol, the hormonal landscape of the body has a profound and under-studied impact on how ADHD presents, fluctuates, and is managed — particularly in women.
Why Women Are at the Centre of This Conversation
ADHD in girls and women remains significantly under-recognised and under-researched, despite increasing clinical awareness. A landmark 2025 review by Kooij et al., published in Frontiers in Global Women's Health (PMID: 40692967), compiled evidence from the Eunethydis Special Interest Group on Female ADHD and confirmed that hormonal transitions — puberty, the menstrual cycle, pregnancy, and perimenopause — consistently exacerbate ADHD symptoms and mood disturbances, yet pharmacological research and tailored treatments remain lacking. The review highlighted how oestrogen and progesterone interact with dopaminergic pathways, and how periods of lower oestrogen can impair cognition in ways that are especially consequential for women with ADHD.
Part of the problem is diagnostic: sociocultural factors and the male-skewed profile of classic ADHD symptoms have led to delayed diagnoses in women. Undiagnosed women, the same review found, face elevated vulnerability to premenstrual dysphoric disorder (PMDD), postpartum depression, and cardiovascular disease during perimenopause — a cascade of consequences that flows directly from the intersection of ADHD and reproductive hormones going unrecognised.
Estrogen, Dopamine, and the Brain
To understand why hormones affect ADHD, it helps to understand the core neurobiology. ADHD is fundamentally linked to dysregulation of the dopaminergic and noradrenergic systems — the neural pathways governing attention, motivation, impulse control, and executive function. Estrogen acts as a natural modulator of these very same pathways.
Estrogen supports dopamine synthesis, release, and receptor density in the prefrontal cortex — the brain region most central to executive function and attentional control. When estrogen levels are high (such as during the follicular phase of the menstrual cycle), dopaminergic transmission is more robust, and many women with ADHD report feeling sharper, more focused, and more in control. When estrogen drops — during the luteal phase, after ovulation, or during perimenopause — that dopaminergic support recedes, and ADHD symptoms tend to worsen.
This mechanism is central to a 2025 narrative review by Wynchank et al. published in the Journal of Clinical Medicine (PMID: 41517370). Their review, which examined 29 studies published between 2015 and 2025, found that women with ADHD experience pronounced hormone-related cognitive difficulties, with menstrual cycle-related changes in mood and cognition interfering with daily functioning and even diminishing the efficacy of ADHD medication. Specifically, impairments in attention, executive function, and impulsivity were consistently observed during the mid-luteal and pre-menstrual phases — precisely when estrogen is declining and progesterone is dominant.
The Menstrual Cycle: A Monthly ADHD Fluctuation
For many women with ADHD, the menstrual cycle functions like a recurring hormonal stress test. The Wynchank et al. review noted that while women without ADHD sometimes show enhanced attentional processing during the mid-luteal phase (possibly linked to higher progesterone), women with ADHD do not appear to share this compensatory benefit. Instead, they are more sensitive to allopregnanolone (a neurosteroid derived from progesterone) and to peri-menstrual oestrogen withdrawal — a combination that amplifies cognitive and emotional symptoms.
This cycle-linked worsening is not merely subjective. Women consistently report heightened mood symptoms and diminished medication efficacy during the luteal phase, and the review found that objective neurobiological measurements — including hormonal assays and neuroimaging — supported these experiences.
A related study by Haimov-Kochman and Berger (2014), published in Frontiers in Human Neuroscience (PMID: 24744721), proposed that ADHD could serve as a model for understanding how sex hormones modulate neuro-developmental cognitive function throughout the cycle — suggesting that regularly cycling women with and without ADHD may experience meaningfully different cognitive profiles depending on where they are in their cycle.
ADHD and PMDD: A Significant Comorbidity
Perhaps one of the most striking findings in recent research is the strong co-occurrence of ADHD and premenstrual dysphoric disorder (PMDD) — a severe, hormonally driven mood disorder that occurs in the days before menstruation.
A 2025 cross-sectional study by Broughton et al., published in the British Journal of Psychiatry (PMID: 40528384), surveyed 715 women aged 18-34 and found that the prevalence of provisional PMDD was 31.4% among women with a clinical ADHD diagnosis and 41.1% among those meeting symptom-based ADHD criteria — compared to just 9.8% in the non-ADHD reference group. Women with both ADHD and depression or anxiety were at the highest risk, with a relative risk of 4.53 compared to those without ADHD.
Puberty, Pregnancy, and Perimenopause: Hormonal Transitions Across the Lifespan
The hormone-ADHD relationship is not limited to the monthly cycle — it plays out across all major reproductive transitions.
Puberty represents the first significant hormonal shift that can unmask or worsen ADHD symptoms in girls. As the ovarian hormones ramp up for the first time, many girls who had previously managed their inattentiveness find their symptoms escalating alongside the emotional and cognitive demands of adolescence.
Pregnancy introduces a complex hormonal environment. While the sustained elevation of estrogen during pregnancy can initially improve mood and focus for some women with ADHD, the postpartum crash in estrogen can trigger or worsen mood disorders and cognitive difficulties. The 2025 Kooij et al. review specifically highlighted postpartum depression as an elevated risk for undiagnosed women with ADHD.
Perimenopause and menopause represent another significant inflection point. As estrogen levels become erratic and then chronically low, many women report that their cognitive symptoms — brain fog, forgetfulness, difficulty concentrating — worsen substantially. Some are diagnosed with ADHD for the first time at this life stage.
A 2025 study by Chapman et al. in the Journal of Attention Disorders (PMID: 40738484) explored this relationship in 656 women aged 45-60, including 245 with an ADHD diagnosis. While the study found no statistically significant group-level difference in menopausal complaints between women with and without ADHD, it did find significant correlations between ADHD symptom severity and menopausal complaints across all participants.
Cortisol and the Stress Hormone Connection
Hormonal involvement in ADHD is not limited to the sex hormones. The stress hormone cortisol — produced by the hypothalamic-pituitary-adrenal (HPA) axis — also shows meaningful dysregulation in ADHD, with important sex-specific nuances.
A 2024 study by Pauli-Pott et al., published in European Child and Adolescent Psychiatry (PMID: 36917355), examined hair cortisol concentrations in 205 medication-naive children — 98 with ADHD and 107 healthy controls. The results revealed a striking sex-by-subtype interaction: boys with predominantly inattentive ADHD showed lower cortisol concentrations than healthy boys, while girls with the combined presentation of ADHD showed higher cortisol concentrations than healthy girls.
A blunted or dysregulated cortisol stress response has broader implications for emotional regulation, sleep, immune function, and the body's ability to modulate attention — all domains central to ADHD. Importantly, chronic stress can further dysregulate these systems, creating a feedback loop in which the demands of daily life with unmanaged ADHD contribute to hormonal dysregulation, which in turn worsens ADHD symptoms.
Thyroid Hormones: An Underexplored Connection
Thyroid hormones represent another piece of the puzzle. The thyroid gland produces hormones that regulate metabolism, mood, energy, and cognitive function — and thyroid dysfunction can produce symptoms that closely mimic ADHD, including difficulty concentrating, mental fatigue, impulsivity, and emotional dysregulation.
A 2025 study by Custodio et al. in Molecular Neurobiology (PMID: 40493342) explored the role of thyroid hormone-responsive proteins in the striatum — a key region implicated in ADHD — using a mouse model of predominantly inattentive ADHD. Their proteomic analysis found that thyroid hormone signalling pathways were involved in regulating synaptic transmission in the striatum, suggesting a biological mechanism by which thyroid hormones could modulate ADHD-related symptomatology.
What This Means for Diagnosis and Treatment
The cumulative picture from this research is clear and clinically important: ADHD is not a hormonally neutral condition. For women especially, understanding hormonal fluctuations is essential to understanding — and managing — ADHD across the lifespan.
Diagnostic assessments should take hormonal context into account, recognising that symptom severity can legitimately vary across the menstrual cycle, across life stages, and in response to hormonal events like pregnancy and menopause. Women with treatment-resistant ADHD, or whose medication seems to work inconsistently, may benefit from tracking their cycles alongside their symptom patterns. Clinicians should also be alert to the high comorbidity between ADHD and conditions like PMDD, postpartum depression, and perimenopausal mood disruption.
The 2025 Kooij et al. review called for longitudinal, sex-specific studies incorporating hormonal status, and for individualised interventions to address the unique needs of girls and women with ADHD. Some researchers are already exploring female-specific treatment strategies, including premenstrual adjustment of psychostimulant dosage.
The Bottom Line
ADHD has long been understood as a condition of the brain, specifically its dopaminergic pathways. But those pathways don't exist in isolation — they are continuously influenced by the body's hormonal environment. Estrogen, progesterone, cortisol, and thyroid hormones all shape the neurochemical landscape in which attention, impulse control, and executive function operate. For women living with ADHD, this biological reality has been too long overlooked.
The research reviewed here — from cycle-specific cognitive fluctuations to the elevated prevalence of PMDD in women with ADHD, from cortisol axis dysregulation to the emerging role of thyroid hormone signalling — points toward a richer, more complete model of ADHD. One that doesn't stop at the brain, but follows the hormones too.
References
- Kooij JJS, et al. Research advances and future directions in female ADHD: the lifelong interplay of hormonal fluctuations with mood, cognition, and disease. Front Glob Womens Health. 2025. PMID: 40692967.
- Wynchank D, et al. Menstrual Cycle-Related Hormonal Fluctuations in ADHD: Effect on Cognitive Functioning. J Clin Med. 2025;15(1):121. PMID: 41517370.
- Broughton T, et al. Increased risk of provisional PMDD among females with ADHD. Br J Psychiatry. 2025;226(6):410-417. PMID: 40528384.
- Chapman L, et al. Examining the Link Between ADHD Symptoms and Menopausal Experiences. J Atten Disord. 2025;29(14):1263-1277. PMID: 40738484.
- Pauli-Pott U, et al. Long-term cortisol secretion in ADHD: roles of sex, comorbidity, and symptom presentation. Eur Child Adolesc Psychiatry. 2024;33(2):569-579. PMID: 36917355.
- Custodio RJP, et al. Unraveling Predominantly Inattentive ADHD: Insights from Proteomic Analysis of the Striatum. Mol Neurobiol. 2025;62(10):13225-13249. PMID: 40493342.
- Haimov-Kochman R, Berger I. Cognitive functions of regularly cycling women may differ throughout the month. Front Hum Neurosci. 2014;8:191. PMID: 24744721.
